One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker ...

Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

The demand for weight loss medications are on the rise, and now, “natural” GLP-1s are being marketed to help you lose weight.

But that's about to change, as weight-loss treatments will soon be available in pill form. RELATED: What Really Happens If ...

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are ...

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster ...

GLP-1RA vs insulin use was associated with improved cardiovascular and kidney outcomes among patients with type 2 diabetes on dialysis.

to examine potential applications of glucagon-like peptide-1 receptor (GLP-1R) agonists in central nervous system disorders, such as dementia, Parkinson’s disease, substance and alcohol use disorders, ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...